LTB4R2 Activators
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LTB4 (Leukotriene B4) | 71160-24-2 | sc-201043 | 50 µg | $374.00 | 4 | |
Leukotriene B4 (LTB4) acts as a potent signaling molecule, primarily engaging with the LTB4 receptor 2 (LTB4R2) to mediate inflammatory responses. Its unique structure allows for specific binding interactions, triggering intracellular pathways that amplify immune cell activation. The compound's hydrophobic nature influences its diffusion across cellular membranes, while its rapid degradation in biological systems highlights its transient signaling role. LTB4's distinct conformational flexibility further facilitates diverse receptor interactions, modulating various physiological processes. | ||||||
12-epi Leukotriene B4 | 83709-73-3 | sc-204980 sc-204980A | 25 µg 50 µg | $176.00 $334.00 | ||
12-epi Leukotriene B4 is a bioactive lipid that selectively interacts with the LTB4 receptor 2 (LTB4R2), influencing cellular signaling cascades. Its unique stereochemistry enhances receptor affinity, promoting distinct downstream effects in immune modulation. The compound exhibits rapid metabolic turnover, underscoring its role in acute inflammatory responses. Additionally, its amphipathic characteristics facilitate membrane interactions, impacting cellular uptake and distribution. | ||||||
Montelukast Sodium | 151767-02-1 | sc-202231 sc-202231A sc-202231B | 10 mg 25 mg 250 mg | $51.00 $85.00 $161.00 | 5 | |
Montelukast, a leukotriene receptor antagonist, binds competitively to leukotriene receptors such as LTB4R2, preventing the binding of leukotrienes like LTB4. This results in the upregulation of LTB4R2 due to the lack of its natural ligand, leading to a compensatory increase in receptor sensitivity and functional activity. | ||||||
Zileuton | 111406-87-2 | sc-204417 sc-204417A sc-204417B sc-204417C | 10 mg 50 mg 1 g 75 g | $84.00 $307.00 $369.00 $1254.00 | 8 | |
Zileuton, a 5-lipoxygenase inhibitor, decreases the synthesis of leukotrienes from arachidonic acid. This reduction in leukotriene production could lead to a similar compensatory upregulation of LTB4R2 as the endogenous ligand levels decrease. | ||||||
SR 48692 | 146362-70-1 | sc-363290 sc-363290A sc-363290B sc-363290C sc-363290D | 5 mg 25 mg 100 mg 500 mg 1 g | $159.00 $605.00 $2374.00 $10710.00 $21410.00 | 2 | |
CP-105696 acts as an LTB4R2 antagonist. By competitively inhibiting the binding of natural leukotriene ligands, it may induce a compensatory upregulation of LTB4R2, thus enhancing receptor activity upon ligand re-exposure. | ||||||
MK-571 | 115103-85-0 | sc-201340 sc-201340A | 5 mg 25 mg | $109.00 $421.00 | 8 | |
MK-571 is a selective leukotriene D4 receptor antagonist, which may cross-react with LTB4R2. This cross-reactivity can lead to a compensatory regulatory increase in LTB4R2 activity due to reduced ligand-receptor interaction. | ||||||